Global AI Drug Repurposing Platform Market Strategic Research Report

Scope of the Report

The global AI Drug Repurposing Platform market size is predicted to grow from US$ 1,272 million in 2025 to US$ 6,472 million in 2032; it is expected to grow at a CAGR of 25.4% from 2026 to 2032.

An AI drug repurposing platform is a computational analytics system for approved drugs, clinical-stage assets and shelved compounds. It integrates biomedical knowledge graphs, omics data, clinical trials, real-world data, literature and patent information, and uses machine learning, network medicine, causal inference and large language models to identify new drug-disease links, indication expansion opportunities, combination-therapy leads and translational evidence. It mainly serves pharmaceutical companies, biotechs, research institutes and foundations in pipeline reassessment, rare-disease development and asset rescue, with a blended gross margin of about 65%.

Demand is mainly driven by pharmaceutical cost reduction, redevelopment of existing assets under patent-cliff pressure, rare-disease and niche-indication development, and public-health response scenarios. Compared with de novo drug discovery, repurposing platforms re-rank drug-disease relationships on the basis of existing safety, pharmacokinetic and clinical experience, making them easier to move into proof-of-concept validation, indication expansion and out-licensing discussions.

The supply side is moving from simple literature mining or similarity search toward integrated knowledge graphs, multi-omics, real-world data, clinical-trial data and explainable models. Buyers evaluate not only algorithmic hit rates, but also data coverage, evidence traceability, private-data integration, API or private deployment, security compliance and wet-lab validation capability. Suppliers that combine platform software, expert services and experimental validation loops are better positioned for long-term partnerships.

Regional demand is led by large pharmaceutical companies, biotechs and research foundations in North America and Europe, while Asia-Pacific is benefiting from local innovative-drug pipelines and rising investment in AI-enabled pharma. Key risks include public-data bias, real-world-data compliance, verifiability of predictions and complex commercial rights around candidate drugs, but the return on investment remains attractive for customers with shelved assets, indication-expansion needs and rare-disease programs.

Report Scope

This report presents a comprehensive overview of the global AI Drug Repurposing Platform market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Target and Mechanism Mining
• Drug–Disease Matching
• Indication Expansion
• Combination Therapy Prediction
• Evidence Ranking and Validation
• Safety and Translational Assessment

Segment by Data Foundation

• Biomedical Knowledge Graphs
• Multi-Omics Data
• Clinical and Real-World Data
• Literature and Patent Data
• Chemical and Target Interaction Data
• Integrated Multimodal Data

Segment by Algorithmic Method

• Knowledge Graph Reasoning
• Machine Learning Prediction
• Network Medicine Analysis
• Causal Inference Modeling
• Generative and Language Models
• Hybrid Expert-in-the-Loop Models

Segment by Delivery Mode

• SaaS Platform
• Private Deployment
• API and Data Service
• Project-Based Collaboration
• Platform with Wet-Lab Validation

Segment by Application

• Rare Disease Repurposing
• Oncology Indication Expansion
• Infectious Disease Response
• CNS and Neurology Research
• Immunology and Inflammation Research
• Asset Rescue and Pipeline Optimization

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global AI Drug Repurposing Platform market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Rare Disease Repurposing, Oncology Indication Expansion, Infectious Disease Response evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact